EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice

Lucía Alascio, Ana Belén Azuaga-Piñango, Beatriz Frade-Sosa iD, Juan C Sarmiento-Monroy, Andrés Ponce iD, Sandra Farietta, Jose A Gómez-Puerta iD, Raimon Sanmartí, Juan D Cañete iD, Julio Ramírez iD

Diagnostics · 30.07.2024 · 14 (15) · 1637

DOI: 10.3390/diagnostics14151637 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 30.07.2024. Verfasst von Lucía Alascio und 9 weiteren Autor:innen. Beteiligte Einrichtung: Arthritis Unit, Rheumatology Department, Hospital Clínic Barcelona, Villarroel Street, 170, 08036 Barcelona, Spain. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriatic arthritis (PsA) is a chronic inflammatory condition affecting about one-third of individuals with psoriasis. Defining axial involvement in PsA (axPsA) remains debated. While rheumatologists guide clinical practice, consensus on axPsA is still lacking. This paper explores historical and upcoming definitions from the Axial Involvement in Psoriatic Arthritis (AXIS) study, which aims to establish a validated axPsA definition. Epidemiological data reveal diverse axPsA prevalence rates, emphasizing its complex relationship with peripheral arthritis and enthesitis. Unique genetic, clinical, and radiological features differentiate axPsA from ankylosing spondylitis (AS), necessitating refined classification criteria. The recommendations from the Assessment of Spondylarthritis international Society (ASAS) provide valuable guidance due to the limited direct evidence. Emerging therapies, including interleukin-23 (IL-23) inhibitors or Janus kinase (JAK) inhibitors, are under investigation for axPsA. Currently, secukinumab, an interleukin-17 (IL-17) inhibitor, is an evidence-based option for axPsA management. However, given the variability in individual patient responses and disease manifestations, personalized, evidence-based treatment approaches remain essential for optimizing patient outcomes. In the final section, two real-life cases illustrate the challenges in managing axPsA, emphasizing the importance of tailored therapies. Achieving precision in defining axPsA remains a formidable task, making detailed criteria essential for effective strategies and improving patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

biological therapypsoriatic arthritisspondyloarthritis

Autor:innen und Institutionen

  • Arthritis Unit, Rheumatology Department, Hospital Clínic Barcelona, Villarroel Street, 170, 08036 Barcelona, Spain.

ORCID-Profile: Beatriz Frade-Sosa, Andrés Ponce, Jose A Gómez-Puerta, Juan D Cañete, Julio Ramírez

Zitieren

APA

Alascio, L., Azuaga-Piñango, A. B., Frade-Sosa, B., Sarmiento-Monroy, J. C., Ponce, A., Farietta, S., Gómez-Puerta, J. A., Sanmartí, R., Cañete, J. D., & Ramírez, J. (2024). Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice. Diagnostics, 14(15), 1637. https://doi.org/10.3390/diagnostics14151637

Vancouver

Alascio L, Azuaga-Piñango AB, Frade-Sosa B, Sarmiento-Monroy JC, Ponce A, Farietta S, et al. Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice. Diagnostics. 2024;14(15):1637. doi:10.3390/diagnostics14151637

BibTeX
@article{Alascio2024,
  author = {Alascio, Lucía and Azuaga-Piñango, Ana Belén and Frade-Sosa, Beatriz and Sarmiento-Monroy, Juan C and Ponce, Andrés and Farietta, Sandra and Gómez-Puerta, Jose A and Sanmartí, Raimon and Cañete, Juan D and Ramírez, Julio},
  title = {Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice},
  journal = {Diagnostics},
  year = {2024},
  volume = {14},
  number = {15},
  pages = {1637},
  doi = {10.3390/diagnostics14151637}
}
Kostenlos starten →